Alkhunaizi Ahmed M, Al-Khouzaie Thamer H, Alsagheir Ahmed I
Nephrology Section, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Pulmonary Section, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Respir Med Case Rep. 2020 Jun 2;30:101109. doi: 10.1016/j.rmcr.2020.101109. eCollection 2020.
Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sirolimus than with everolimus in the literature, possibly due to earlier introduction and wider use of sirolimus. We report the case of a kidney transplant recipient who developed ILD secondary to sirolimus and improved rapidly after switching to everolimus.
雷帕霉素哺乳动物靶点抑制剂（mTORi）用于治疗多种恶性肿瘤，并在器官移植中发挥着既定作用。间质性肺病（ILD）是mTORi的并发症之一，被认为是一种类效应。文献报道中，与依维莫司相比，西罗莫司导致的ILD病例更多，这可能是由于西罗莫司更早引入且使用更广泛。我们报告了一例肾移植受者，该患者因西罗莫司继发ILD，在换用依维莫司后迅速好转。
